DNA IL-12: Phase I data

Data from 24 patients in an open-label, dose-escalation, U.S. Phase I trial showed that 0.1, 0.25, 0.5, 1 and 1.6 mg/mL DNA IL-12 delivered directly into tumors with the company’s OMS ElectroImmunothe...